Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is one of the 20 Best Performing Stocks in 2025. Needham analyst Ami Fadia maintained a Buy rating on PRAX and raised the price target from $315 to $460 on January 5, 2026. The firm expects more new drug applications in 2026, particularly for ulixacaltamide for essential tremor treatment. Jefferies analyst Andrew Tsai also praised the FDA granting Breakthrough Therapy Designation for ulixacaltamide, increasing its chances of success. PRAX is a clinical-stage biopharmaceutical company with significant growth potential. No promotional content is included in this news summary.

Read more at Yahoo Finance: Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX)